Bolt Biotherapeutics is a clinical-stage biopharmaceutical company developing immunotherapies for the treatment of cancer.. Co.'s proprietary Boltbody ISAC (immune-stimulating antibody conjugate) platform technology combines tumor-targeting antibodies with immune-stimulating linker payloads to create productive anti-tumor immune responses. Co.'s lead product candidate, BDC-1001, is in clinical development for the treatment of patients with human epidermal growth factor receptor 2 (HER2)-expressing solid tumors, including gastroesophageal cancer. Co.'s second program, BDC-3042, is an agonist antibody targeting Dectin-2, an innate immune receptor found on the surface of macrophages. The BOLT average annual return since 2021 is shown above.
The Average Annual Return on the BOLT average annual return since 2021 page and across the coverage universe of our site,
is a measure of the annualized return over the past ten years (or specified start date) for a given investment
(up to the end of prior trading session recorded). Arguably, choosing ten years for a measurement
period is on the one hand completely arbitrary, but on the other hand provides a sufficiently long window
to capture long-term trends.
Thus, researching Average Annual Returns is good practice for investors — whether BOLT average annual return since 2021 or other benchmarks/peers
— and when doing so it is also important to factor in dividends, because a financial instrument's annualized return is
more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors
by performing the BOLT average annual return calculation with any dividends reinvested as applicable (on ex-dates).
|